FDA approves Lilly Reyvow tablets to be available for treatment in adult migraine sufferers

today, Lilly(http:// announcedthat the U.SFDA(http://approved the company's development of Reyvow tablets as an early or no-foreboding adult migraine treatment for acute treatmentAbout Reyvow
Reyvow has a unique mechanism of action and is the first and only FDA-approved serotonin (5-HT) 1F receptor agonistReyvow, developed by Lilly, is an innovative oral 5-HT1F receptor agonistIt can be combined with 5-HT1F receptors with high affinityReyvow is the first FDA-approveddrug(http://The current common acute treatment for migraines is triptans, a 5-HT1B/1D receptor agonist, and although they have significant effects in relieving migraines, activating the 5-HT1B receptor subtype can have an gioconstrictation effect and other side effectsReyvow does not activate the 5-HT1B receptor and therefore does not have an vascular contraction effectIt is safer for migraine sufferers with cardiovascular disease or at risk of cardiovascular diseaseReyvow's efficacy was demonstrated in two randomized double-blind, placebo-controlled phase 3 clinical trials (HTTP://WWW.CHEMDRUG.COM/SELL/24/) (SAMURAI and SPARTAN) 3,177 patients with a history of migraines participated in both clinical trials The results showed that the proportion of patients with a complete loss of headache after 2 hours of administration significantly increased compared to the placebo group, and that Reyvow significantly eliminated migraine symptoms (nausea and sound sensitivity) in other patients most troubled